Division of Cardinal Health Inc.
Latest From AccessClosure Inc.
The $1 billion vascular closure market is primed for growth. It comes on the back of intensive R&D that has spawned a range of alternatives to the traditional manual/compression approach, giving SJM and the sector’s other heavyweights cause to look over their shoulders.
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
With an annual growth of almost 5%, the market for vascular access site repair products is attracting companies with innovative new products. Wider acceptance of new approaches to wound closure by interventionalists and the under-penetration in emerging Asian markets in particular are resulting in an uptake in the use of higher-tech devices and the emergence of local manufacturers.
Surgical Equipment & Devices
- Surgical Sealants
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Cardinal Health Inc.
- Senior Management
Gregory D Casciaro, Pres. & CEO
John J Buckley, CFO
Susan Aloyan, EVP, Reg., Clin., & Quality Affairs
Stephen MacKinnon, VP, Sales
- Contact Info
Phone: (408) 610-6500
5452 Betsy Ross Dr.
Santa Clara, CA 95054
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.